

AS. 151.789

Señora Directora
DIRECCIÓN DE NUEVAS CREACIONES
SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

RESPUESTA A OFICIO No. 5806 DEL 26 DE ABRIL DE 2022

REF: Expediente No. NC2022/0004797 - Solicitud de Patente Fase Nacional
A favor de **GENENTECH INC.**
Titulada: ANTICUERPOS ANTI-KLK7, ANTICUERPOS ANTI-KLK5, ANTICUERPOS
MULTIESPECÍFICOS ANTI-KLK5/KLK7 Y MÉTODOS DE USO

JUAN PABLO CADENA SARMIENTO, vecino de Bogotá, portador de la tarjeta profesional No. 57492, obrando como apoderado de la sociedad **GENENTECH INC.**, según lo acredita el documento de poder presentado en esa Dirección, para dar cumplimiento al requerimiento notificado de manera automática el 27 de abril de 2022, de acuerdo con los Artículos 38 y 39 de la Decisión 486 de la comisión de la Comunidad Andina, me permito allegar:

1. Documento donde consta la cesión del derecho a la Patente otorgado por los inventores al solicitante.

De la señora Directora atentamente,



JUAN PABLO CADENA SARMIENTO
C.C. No. 80.410.337 de Usaquén
T. P. 57.492 del Consejo Superior de la Judicatura

Bogotá, 16 de junio de 2022
JPC/jpg

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6402971

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
JAMES THOMAS KOERBER	12/02/2019
WYNE PUN LEE	12/02/2019
TANGSHENG YI	12/02/2019
JUAN ZHANG	12/02/2019
CARY DEAN AUSTIN	12/02/2019
CECILIA P.C. CHIU	12/02/2019
JOSEPH EDWARD CHAVARRIA-SMITH	09/23/2020
JAWAHAR SUDHAMSU	10/06/2020
RECEIVING PARTY DATA	
Name:	GENENTECH, INC.
Street Address:	1 DNA WAY
City:	SOUTH SAN FRANCISCO
State/Country:	CALIFORNIA
Postal Code:	94080-4990
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	17024094
PCT Number:	US2020051233
CORRESPONDENCE DATA	
Fax Number:	(650)952-9881
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	650-225-2497
Email:	nikkin@gene.com
Correspondent Name:	NIKKI NOMURA
Address Line 1:	1 DNA WAY, MS-49
Address Line 2:	C/O GENENTECH, INC.
Address Line 4:	SOUTH SAN FRANCISCO, CALIFORNIA 94080
ATTORNEY DOCKET NUMBER:	P35683-US-1 & P35683-WO
NAME OF SUBMITTER:	NIKKI NOMURA

PATENT

CONFIRMATORY ASSIGNMENT

WHEREAS, **James Thomas KOERBER** ("ASSIGNOR"), has invented new and useful invention(s) as set forth in the applications listed in Exhibit A (including any updated Exhibit A as provided herein), to this Confirmatory Assignment (the "**INVENTION**"), for which application(s) has been filed as identified on **Exhibit A** (including any updated Exhibit A as provided herein); and

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, United States of America, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, United States of America, ("**GENENTECH**"), is desirous of confirming its ownership interest in and to the INVENTION and in and to the applications and patents to be obtained therefor, or, if ASSIGNOR has not assigned his or her interest in the INVENTION to GENENTECH pursuant to a prior agreement with GENENTECH, acquiring an interest in and to the INVENTION, and in and to the applications and patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

For good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR confirms that prior to, and no later than the earliest filing date of the applications listed in Exhibit A (including any updated Exhibit A as provided herein), ASSIGNOR had assigned to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which that application claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.


To the extent that ASSIGNOR has not already assigned all of his or her rights, title and interest in the INVENTION to GENENTECH via a prior agreement with GENENTECH, then for good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR does hereby assign to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which those application(s) claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

The ASSIGNOR agrees and authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR. ASSIGNOR agrees and acknowledges that such updated Exhibit A is an Exhibit A under this Confirmatory Assignment.

The terms and covenants of this Confirmatory Assignment shall inure to the benefit of GENENTECH, its successors, assigns or delegates, and shall be binding upon the ASSIGNOR, his or her respective heirs, successors and assigns.

This Confirmatory Assignment shall be governed by the substantial laws of California (excluding its conflicts of law principles).

IN WITNESS WHEREOF on this date of 2 December 2019 the ASSIGNOR and GENENTECH have executed this Confirmatory Assignment and accepted the terms thereof:



James Thomas KOERBER

Mailing address:

1 DNA Way

South San Francisco, CA 94080

Citizenship: US



GENENTECH, INC.

Rebecca J. Wais

Assistant General Counsel

Genentech, Inc.

Authorized Corporate Signatory

EXHIBIT A TO CONFIRMATORY ASSIGNMENT*

Docket No.	Title	Serial Number	Filing Date
P35683-US	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	62/901990	18 September 2019

*As agreed in this Confirmatory Assignment, ASSIGNOR hereby authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR.

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date
P35683-US	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	62/901990	18 September 2019
P35683-US-1	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	17/024094	17 September 2020
P35683-WO	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	PCT/US2020/051233	17 September 2020
P35683-AR	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	P200102585	17 September 2020
P35683-GC	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	40476	17 September 2020
P35683-TW	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	109132166	17 September 2020

CONFIRMATORY ASSIGNMENT

WHEREAS, **Wyne Pun LEE** ("ASSIGNOR"), has invented new and useful invention(s) as set forth in the applications listed in Exhibit A (including any updated Exhibit A as provided herein), to this Confirmatory Assignment (the "**INVENTION**"), for which application(s) has been filed as identified on **Exhibit A** (including any updated Exhibit A as provided herein); and

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, United States of America, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, United States of America, ("**GENENTECH**"), is desirous of confirming its ownership interest in and to the INVENTION and in and to the applications and patents to be obtained therefor, or, if ASSIGNOR has not assigned his or her interest in the INVENTION to GENENTECH pursuant to a prior agreement with GENENTECH, acquiring an interest in and to the INVENTION, and in and to the applications and patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

For good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR confirms that prior to, and no later than the earliest filing date of the applications listed in Exhibit A (including any updated Exhibit A as provided herein), ASSIGNOR had assigned to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which that application claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.


To the extent that ASSIGNOR has not already assigned all of his or her rights, title and interest in the INVENTION to GENENTECH via a prior agreement with GENENTECH, then for good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR does hereby assign to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which those application(s) claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

The ASSIGNOR agrees and authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR. ASSIGNOR agrees and acknowledges that such updated Exhibit A is an Exhibit A under this Confirmatory Assignment.

The terms and covenants of this Confirmatory Assignment shall inure to the benefit of GENENTECH, its successors, assigns or delegates, and shall be binding upon the ASSIGNOR, his or her respective heirs, successors and assigns.

This Confirmatory Assignment shall be governed by the substantial laws of California (excluding its conflicts of law principles).

IN WITNESS WHEREOF on this date of 2 December 2019 the ASSIGNOR and GENENTECH have executed this Confirmatory Assignment and accepted the terms thereof:




Wyne Pun LEE

Mailing address:

1 DNA Way

South San Francisco, CA 94080

Citizenship: US



GENENTECH, INC.

Rebecca J. Wais

Assistant General Counsel

Genentech, Inc.

Authorized Corporate Signatory

EXHIBIT A TO CONFIRMATORY ASSIGNMENT*

Docket No.	Title	Serial Number	Filing Date
P35683-US	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	62/901990	18 September 2019

*As agreed in this Confirmatory Assignment, ASSIGNOR hereby authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR.

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date
P35683-US	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	62/901990	18 September 2019
P35683-US-1	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	17/024094	17 September 2020
P35683-WO	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	PCT/US2020/051233	17 September 2020
P35683-AR	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	P200102585	17 September 2020
P35683-GC	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	40476	17 September 2020
P35683-TW	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	109132166	17 September 2020

CONFIRMATORY ASSIGNMENT

WHEREAS, **Tangsheng Yi** ("ASSIGNOR"), has invented new and useful invention(s) as set forth in the applications listed in Exhibit A (including any updated Exhibit A as provided herein), to this Confirmatory Assignment (the "INVENTION"), for which application(s) has been filed as identified on **Exhibit A** (including any updated Exhibit A as provided herein); and

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, United States of America, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, United States of America, ("**GENENTECH**"), is desirous of confirming its ownership interest in and to the INVENTION and in and to the applications and patents to be obtained therefor, or, if ASSIGNOR has not assigned his or her interest in the INVENTION to GENENTECH pursuant to a prior agreement with GENENTECH, acquiring an interest in and to the INVENTION, and in and to the applications and patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

For good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR confirms that prior to, and no later than the earliest filing date of the applications listed in Exhibit A (including any updated Exhibit A as provided herein), ASSIGNOR had assigned to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which that application claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.


To the extent that ASSIGNOR has not already assigned all of his or her rights, title and interest in the INVENTION to GENENTECH via a prior agreement with GENENTECH, then for good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR does hereby assign to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which those application(s) claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

The ASSIGNOR agrees and authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR. ASSIGNOR agrees and acknowledges that such updated Exhibit A is an Exhibit A under this Confirmatory Assignment.

The terms and covenants of this Confirmatory Assignment shall inure to the benefit of GENENTECH, its successors, assigns or delegates, and shall be binding upon the ASSIGNOR, his or her respective heirs, successors and assigns.

This Confirmatory Assignment shall be governed by the substantial laws of California (excluding its conflicts of law principles).

IN WITNESS WHEREOF on this date of 2 December 2019 the ASSIGNOR and GENENTECH have executed this Confirmatory Assignment and accepted the terms thereof:




Tangsheng Yi

Mailing address:

1 DNA Way

South San Francisco, CA 94080

Citizenship: CN



GENENTECH, INC.

Rebecca J. Wals

Assistant General Counsel

Genentech, Inc.

Authorized Corporate Signatory

EXHIBIT A TO CONFIRMATORY ASSIGNMENT*

Docket No.	Title	Serial Number	Filing Date
P35683-US	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	62/901990	18 September 2019

*As agreed in this Confirmatory Assignment, ASSIGNOR hereby authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR.

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date
P35683-US	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	62/901990	18 September 2019
P35683-US-1	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	17/024094	17 September 2020
P35683-WO	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	PCT/US2020/051233	17 September 2020
P35683-AR	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	P200102585	17 September 2020
P35683-GC	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	40476	17 September 2020
P35683-TW	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	109132166	17 September 2020

CONFIRMATORY ASSIGNMENT

WHEREAS, **Juan ZHANG** ("**ASSIGNOR**"), has invented new and useful invention(s) as set forth in the applications listed in Exhibit A (including any updated Exhibit A as provided herein), to this Confirmatory Assignment (the "**INVENTION**"), for which application(s) has been filed as identified on **Exhibit A** (including any updated Exhibit A as provided herein); and

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, United States of America, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, United States of America, ("**GENENTECH**"), is desirous of confirming its ownership interest in and to the INVENTION and in and to the applications and patents to be obtained therefor, or, if ASSIGNOR has not assigned his or her interest in the INVENTION to GENENTECH pursuant to a prior agreement with GENENTECH, acquiring an interest in and to the INVENTION, and in and to the applications and patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

For good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR confirms that prior to, and no later than the earliest filing date of the applications listed in Exhibit A (including any updated Exhibit A as provided herein), ASSIGNOR had assigned to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which that application claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.


To the extent that ASSIGNOR has not already assigned all of his or her rights, title and interest in the INVENTION to GENENTECH via a prior agreement with GENENTECH, then for good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR does hereby assign to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which those application(s) claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

The ASSIGNOR agrees and authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR. ASSIGNOR agrees and acknowledges that such updated Exhibit A is an Exhibit A under this Confirmatory Assignment.

The terms and covenants of this Confirmatory Assignment shall inure to the benefit of GENENTECH, its successors, assigns or delegates, and shall be binding upon the ASSIGNOR, his or her respective heirs, successors and assigns.

This Confirmatory Assignment shall be governed by the substantial laws of California (excluding its conflicts of law principles).

IN WITNESS WHEREOF on this date of 2 December 2019 the ASSIGNOR and GENENTECH have executed this Confirmatory Assignment and accepted the terms thereof.



Juan ZHANG

Mailing address:

1 DNA Way

South San Francisco, CA 94080

Citizenship: US



GENENTECH, INC.

Rebecca J. Wais

Assistant General Counsel

Genentech, Inc.

Authorized Corporate Signatory

EXHIBIT A TO CONFIRMATORY ASSIGNMENT*

Docket No.	Title	Serial Number	Filing Date
P35683-US	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	62/901990	18 September 2019

*As agreed in this Confirmatory Assignment, ASSIGNOR hereby authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR.

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date
P35683-US	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	62/901990	18 September 2019
P35683-US-1	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	17/024094	17 September 2020
P35683-WO	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	PCT/US2020/051233	17 September 2020
P35683-AR	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	P200102585	17 September 2020
P35683-GC	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	40476	17 September 2020
P35683-TW	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	109132166	17 September 2020

CONFIRMATORY ASSIGNMENT

WHEREAS, **Cary Dean AUSTIN** ("**ASSIGNOR**"), has invented new and useful invention(s) as set forth in the applications listed in Exhibit A (including any updated Exhibit A as provided herein), to this Confirmatory Assignment (the "**INVENTION**"), for which application(s) has been filed as identified on **Exhibit A** (including any updated Exhibit A as provided herein); and

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, United States of America, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, United States of America, ("**GENENTECH**"), is desirous of confirming its ownership interest in and to the INVENTION and in and to the applications and patents to be obtained therefor, or, if ASSIGNOR has not assigned his or her interest in the INVENTION to GENENTECH pursuant to a prior agreement with GENENTECH, acquiring an interest in and to the INVENTION, and in and to the applications and patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

For good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR confirms that prior to, and no later than the earliest filing date of the applications listed in Exhibit A (including any updated Exhibit A as provided herein), ASSIGNOR had assigned to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which that application claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

To the extent that ASSIGNOR has not already assigned all of his or her rights, title and interest in the INVENTION to GENENTECH via a prior agreement with GENENTECH, then for good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR does hereby assign to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which those application(s) claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

The ASSIGNOR agrees and authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR. ASSIGNOR agrees and acknowledges that such updated Exhibit A is an Exhibit A under this Confirmatory Assignment.

The terms and covenants of this Confirmatory Assignment shall inure to the benefit of GENENTECH, its successors, assigns or delegates, and shall be binding upon the ASSIGNOR, his or her respective heirs, successors and assigns.

This Confirmatory Assignment shall be governed by the substantial laws of California (excluding its conflicts of law principles).

IN WITNESS WHEREOF on this date of 2 December 2019 the ASSIGNOR and GENENTECH have executed this Confirmatory Assignment and accepted the terms thereof:



Cary Dean AUSTIN

Mailing address:

1 DNA Way

South San Francisco, CA 94080

Citizenship: United States of America



GENENTECH, INC.

Rebecca J. Wals
Assistant General Counsel
Genentech, Inc.
Authorized Corporate Signatory

EXHIBIT A TO CONFIRMATORY ASSIGNMENT*

Docket No.	Title	Serial Number	Filing Date
P35683-US	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	62/901990	18 September 2019

*As agreed in this Confirmatory Assignment, ASSIGNOR hereby authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR.

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date
P35683-US	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	62/901990	18 September 2019
P35683-US-1	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	17/024094	17 September 2020
P35683-WO	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	PCT/US2020/051233	17 September 2020
P35683-AR	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	P200102585	17 September 2020
P35683-GC	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	40476	17 September 2020
P35683-TW	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	109132166	17 September 2020

CONFIRMATORY ASSIGNMENT

WHEREAS, **Cecilia P.C. CHIU** ("**ASSIGNOR**"), has invented new and useful invention(s) as set forth in the applications listed in Exhibit A (including any updated Exhibit A as provided herein), to this Confirmatory Assignment (the "**INVENTION**"), for which application(s) has been filed as identified on **Exhibit A** (including any updated Exhibit A as provided herein); and

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, United States of America, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, United States of America, ("**GENENTECH**"), is desirous of confirming its ownership interest in and to the INVENTION and in and to the applications and patents to be obtained therefor, or, if ASSIGNOR has not assigned his or her interest in the INVENTION to GENENTECH pursuant to a prior agreement with GENENTECH, acquiring an interest in and to the INVENTION, and in and to the applications and patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

For good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR confirms that prior to, and no later than the earliest filing date of the applications listed in Exhibit A (including any updated Exhibit A as provided herein), ASSIGNOR had assigned to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which that application claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.


To the extent that ASSIGNOR has not already assigned all of his or her rights, title and interest in the INVENTION to GENENTECH via a prior agreement with GENENTECH, then for good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR does hereby assign to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which those application(s) claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

The ASSIGNOR agrees and authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR. ASSIGNOR agrees and acknowledges that such updated Exhibit A is an Exhibit A under this Confirmatory Assignment.

The terms and covenants of this Confirmatory Assignment shall inure to the benefit of GENENTECH, its successors, assigns or delegates, and shall be binding upon the ASSIGNOR, his or her respective heirs, successors and assigns.

This Confirmatory Assignment shall be governed by the substantial laws of California (excluding its conflicts of law principles).

IN WITNESS WHEREOF on this date of 2 December 2019 the ASSIGNOR and GENENTECH have executed this Confirmatory Assignment and accepted the terms thereof:




Cecilia P.C. CHIU

Mailing address:

1 DNA Way

South San Francisco, CA 94080

Citizenship: CA



GENENTECH, INC.

Rebecca J. Wais

Assistant General Counsel

Genentech, Inc.

Authorized Corporate Signatory

EXHIBIT A TO CONFIRMATORY ASSIGNMENT*

Docket No.	Title	Serial Number	Filing Date
P35683-US	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	62/901990	18 September 2019

*As agreed in this Confirmatory Assignment, ASSIGNOR hereby authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR.

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date
P35683-US	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	62/901990	18 September 2019
P35683-US-1	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	17/024094	17 September 2020
P35683-WO	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	PCT/US2020/051233	17 September 2020
P35683-AR	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	P200102585	17 September 2020
P35683-GC	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	40476	17 September 2020
P35683-TW	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	109132166	17 September 2020

CONFIRMATORY ASSIGNMENT

WHEREAS, Joseph Edward CHAVARRIA-SMITH ("**ASSIGNOR**"), has invented new and useful invention(s) as set forth in the applications listed in Exhibit A (including any updated Exhibit A as provided herein), to this Confirmatory Assignment (the "**INVENTION**"), for which application(s) has been filed as identified on **Exhibit A** (including any updated Exhibit A as provided herein); and

WHEREAS, **GENENTECH, INC.**, a corporation organized and existing under and by virtue of the laws of the State of Delaware, United States of America, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, United States of America, ("**GENENTECH**"), is desirous of confirming its ownership interest in and to the **INVENTION** and in and to the applications and patents to be obtained therefor, or, if **ASSIGNOR** has not assigned his or her interest in the **INVENTION** to **GENENTECH** pursuant to a prior agreement with **GENENTECH**, acquiring an interest in and to the **INVENTION**, and in and to the applications and patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

For good and valuable consideration the receipt of which is hereby acknowledged, **ASSIGNOR** confirms that prior to, and no later than the earliest filing date of the applications listed in Exhibit A (including any updated Exhibit A as provided herein), **ASSIGNOR** had assigned to **GENENTECH**, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the **INVENTION**, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which that application claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

To the extent that **ASSIGNOR** has not already assigned all of his or her rights, title and interest in the **INVENTION** to **GENENTECH** via a prior agreement with **GENENTECH**, then for good and valuable consideration the receipt of which is hereby acknowledged, **ASSIGNOR** does hereby assign to **GENENTECH**, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the **INVENTION**, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which those application(s) claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

The **ASSIGNOR** agrees and authorizes **GENENTECH**, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by **GENENTECH**, its successors, assigns and delegates in and to the **INVENTION** when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by **ASSIGNOR**. **ASSIGNOR** agrees and acknowledges that such updated Exhibit A is an Exhibit A under this Confirmatory Assignment.

The terms and covenants of this Confirmatory Assignment shall inure to the benefit of **GENENTECH**, its successors, assigns or delegates, and shall be binding upon the **ASSIGNOR**, his or her respective heirs, successors and assigns.

ASSIGNMENT I-A

Family No.: P35683

Genentech File Identifier: ANTI KLK5, KLK7 and KLK5/7 ANTIBODIES AND USES THEREOF

This Confirmatory Assignment shall be governed by the substantial laws of California (excluding its conflicts of law principles).

IN WITNESS WHEREOF on this date of 23 September 2020, the ASSIGNOR and GENENTECH have executed this Confirmatory Assignment and accepted the terms thereof:




Joseph Edward CHAVARRIA-SMITH

Mailing address:

1 DNA Way

South San Francisco, CA 94080

Citizenship: **US**



GENENTECH, INC.

Kelly B. McClellan

Assistant General Counsel

Genentech, Inc.

Authorized Corporate Signatory

EXHIBIT A TO CONFIRMATORY ASSIGNMENT*

Docket No.	Title	Serial Number	Filing Date
P35683-US-1	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	17/024094	17 September 2020
P35683-WO	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	PCT/US2020/051233	17 September 2020
P35683-AR	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	P200102585	17 September 2020
P35683-GC	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	40476	17 September 2020
P35683-TW	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	109132166	17 September 2020

*As agreed in this Confirmatory Assignment, ASSIGNOR hereby authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR.

ASSIGNMENT I-A

Family No.: P35683

Genentech File Identifier: ANTI KLK5, KLK7 and KLK5/7 ANTIBODIES AND USES THEREOF

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date

CONFIRMATORY ASSIGNMENT

WHEREAS, **Jawahar SUDHAMSU** ("ASSIGNOR"), has invented new and useful invention(s) as set forth in the applications listed in Exhibit A (including any updated Exhibit A as provided herein), to this Confirmatory Assignment (the "**INVENTION**"), for which application(s) has been filed as identified on **Exhibit A** (including any updated Exhibit A as provided herein); and

WHEREAS, **GENENTECH, INC.**, a corporation organized and existing under and by virtue of the laws of the State of Delaware, United States of America, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, United States of America, ("**GENENTECH**"), is desirous of confirming its ownership interest in and to the **INVENTION** and in and to the applications and patents to be obtained therefor, or, if **ASSIGNOR** has not assigned his or her interest in the **INVENTION** to **GENENTECH** pursuant to a prior agreement with **GENENTECH**, acquiring an interest in and to the **INVENTION**, and in and to the applications and patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

For good and valuable consideration the receipt of which is hereby acknowledged, **ASSIGNOR** confirms that prior to, and no later than the earliest filing date of the applications listed in Exhibit A (including any updated Exhibit A as provided herein), **ASSIGNOR** had assigned to **GENENTECH**, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the **INVENTION**, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which that application claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

To the extent that **ASSIGNOR** has not already assigned all of his or her rights, title and interest in the **INVENTION** to **GENENTECH** via a prior agreement with **GENENTECH**, then for good and valuable consideration the receipt of which is hereby acknowledged, **ASSIGNOR** does hereby assign to **GENENTECH**, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the **INVENTION**, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which those application(s) claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

The **ASSIGNOR** agrees and authorizes **GENENTECH**, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by **GENENTECH**, its successors, assigns and delegates in and to the **INVENTION** when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by **ASSIGNOR**. **ASSIGNOR** agrees and acknowledges that such updated Exhibit A is an Exhibit A under this Confirmatory Assignment.

The terms and covenants of this Confirmatory Assignment shall inure to the benefit of **GENENTECH**, its successors, assigns or delegates, and shall be binding upon the **ASSIGNOR**, his or her respective heirs, successors and assigns.


ASSIGNMENT I-A

Family No.: P35683

Genentech File Identifier: ANTI KLK5, KLK7 and KLK5/7 ANTIBODIES AND USES THEREOF

This Confirmatory Assignment shall be governed by the substantial laws of California (excluding its conflicts of law principles).

IN WITNESS WHEREOF on this date of 6 October 2020, the ASSIGNOR and GENENTECH have executed this Confirmatory Assignment and accepted the terms thereof:




Jawahar SUDHAMSU

Mailing address:

1 DNA Way

South San Francisco, CA 94080

Citizenship: **US**



GENENTECH, INC.

Kelly B. McClellan
Assistant General Counsel
Genentech, Inc.
Authorized Corporate Signatory

EXHIBIT A TO CONFIRMATORY ASSIGNMENT*

Docket No.	Title	Serial Number	Filing Date
P35683-US-1	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	17/024094	17 September 2020
P35683-WO	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	PCT/US2020/051233	17 September 2020
P35683-AR	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	P200102585	17 September 2020
P35683-GC	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	40476	17 September 2020
P35683-TW	ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE	109132166	17 September 2020

*As agreed in this Confirmatory Assignment, ASSIGNOR hereby authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR.

ASSIGNMENT I-A

Family No.: P35683

Genentech File Identifier: ANTI KLK5, KLK7 and KLK5/7 ANTIBODIES AND USES THEREOF

UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

Docket No.	Title	Serial Number	Filing Date